The Trump administration has terminated a significant $766 million contract with pharmaceutical giant Moderna for the development of a human bird flu vaccine, the company announced Wednesday. This decision impacts ongoing efforts to prepare for potential avian influenza outbreaks.
This $766 million contract expanded on prior funding: a $176 million deal by the Biden administration for Moderna’s mRNA-based H5N1 shot, later augmented by $590 million from Health and Human Services (HHS) for late-stage development and broader H5N1 subtype trials.
The cancellation aligns with Health Secretary Robert F. Kennedy Jr.’s skepticism of mRNA vaccines, despite data showing millions of lives saved. Moderna also recently withdrew its FDA application for a hybrid COVID-flu shot, and the CDC altered vaccine guidance for children and pregnant women.
Since 2022, H5N1 has led to over 148 million bird culls and spread to wildlife, cows, and humans. The U.S. Centers for Disease Control and Prevention (CDC) reports 70 domestic human cases and one death. Globally, the World Health Organization (WHO) notes a 50% H5N1 case fatality rate.
Amesh Adalja of Johns Hopkins Center for Health Security told Reuters this discards a vital tool against avian flu, contrasting with Trump’s Operation Warp Speed. Moderna stated it will seek alternative development paths and shared positive interim H5N1 trial data.
The termination of this significant funding raises questions about the U.S. strategy for combating potential bird flu pandemics. Moderna intends to continue its vaccine research, emphasizing the ongoing need for effective countermeasures against evolving viral threats.
